Daschle to Spearhead Health Reform Efforts
President-elect Barak Obama selects former Senate majority leader Tom Daschle as secretary of Health and Human Services.
Daschle to Spearhead Health Reform Efforts
President-elect Barak Obama is moving quickly in selecting former Senate majority leader Tom Daschle as secretary of Health and Human Services. Daschle has been a close advisor to Obama and is slated to be the administration’s point person on moving health reform legislation through Congress. Reform advocates consider the selection a sign that the Obama administration will seek to fulfill its promises to make health reform a top priority.
Daschle’s familiarity with health policy issues is evident in the book he co-authored earlier this year: “Critical: What We Can Do about the Health-Care Crisis.” But with less administrative experience than the governors who preceded him, Daschle will need capable deputies to oversee key HHS agencies, including the Food and Drug Administration, the National Institutes of Health and Medicare and Medicaid.
The former Senator from South Dakota lost his seat in a hard-fought battle in 2004. He was criticized then as too much of a Washington insider, and his nomination provoked similar comments from some parties. But most observers regard the appointment as realistic assessment that consummate political skill is needed to reform the nation’s health care system.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
